Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Tevimbra

Tevimbra 100 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 12

HOS-150211 · Präparat HOS-100272

Adverse reactions reported in the pooled dataset for patients treated with Tevimbra monotherapy (N= 1952) and in combination with chemotherapy (N = 1950) are presented in Table 2. Adverse reactions are listed according to system organ class in MedDRA. Within each system organ class, the adverse reactions are presented in decreasing frequency. The corresponding frequency category for each adverse reaction is defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000); not known (cannot be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.